Legal·September 23, 2026·2 min read

GLP-1 users sue over sudden vision loss

European regulators confirm very rare risk for semaglutide drugs

Dozens of Americans have filed lawsuits alleging widely used GLP-1 medications caused non-arteritic anterior ischemic optic neuropathy, or NAION, a condition involving reduced blood flow to the optic nerve that can cause sudden and potentially permanent vision loss. The lawsuits involve popular diabetes and weight-loss drugs, but the scientific and regulatory evidence differs depending on the medication, and the litigation does not establish that every drug named caused the plaintiffs' injuries.

The federal cases have been centralized as MDL 3163 in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston. The court said in July 2026 that more than 130 cases were included in the litigation. Plaintiffs allege GLP-1 medications caused NAION and raise claims including failure to warn, design defects and breach of warranties. The court is examining scientific evidence, regulatory history and whether the drugs can cause the condition.

The strongest regulatory finding applies specifically to semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus. In June 2025, the European Medicines Agency concluded there was sufficient evidence of a causal relationship between semaglutide and NAION and recommended adding it to product information as a very rare side effect, meaning it may affect up to 1 in 10,000 people taking semaglutide. Current European product information includes that warning. Several large studies reviewed by the EMA found approximately a twofold relative increase in risk, corresponding to roughly one additional case per 10,000 person-years of treatment.

The situation remains different in the United States and across the broader GLP-1 class. The U.S. Food and Drug Administration identified NAION as a potential safety signal for GLP-1 receptor agonists, including semaglutide and tirzepatide products, and says it is evaluating whether regulatory action is needed. ABC News reports that research into GLP-1 drugs more broadly remains mixed and no study has established that the entire drug class causes NAION. European regulators advise patients taking semaglutide to contact a doctor without delay for sudden vision loss or rapidly worsening eyesight.

Community discussion
"Does knowing that a serious side effect is very rare change how you weigh a medication's benefits and risks?"